度普利尤单抗在生物制剂经治与初治CRSwNP患者中的真实世界疗效
RELIBIO试验纳入55例接受度普利尤单抗治疗的CRSwNP患者,分为生物制剂初治组30例和经奥马珠单抗或美泊珠单抗治疗6个月无或低应答的转换组25例。两组在6个月时患者报告结局和鼻息肉总分均显著改善,转换组与初治组在SNOT-22、TNPS等指标上疗效相当。转换组67%达良好至优异治疗反应,初治组97%;疾病控制率分别为44%和67%,嗅觉丧失是未控制主因。
要点
- 度普利尤单抗可显著改善转换组和初治组CRSwNP患者的症状与鼻息肉评分。
- 转换组6个月良好至优异治疗反应率67%,低于初治组的97%。
- 转换组疾病控制率44%,初治组67%,嗅觉丧失是未控制主因。
核心结论
- 度普利尤单抗治疗6个月可显著降低转换组和初治组CRSwNP患者的症状严重程度及鼻息肉评分。
- 生物制剂初治组患者获得疾病控制的可能性高于转换组。
研究设计与样本
- RELIBIO试验前瞻性真实世界研究,纳入55例接受度普利尤单抗治疗的CRSwNP患者。
- 生物制剂初治组30例,对奥马珠单抗或美泊珠单抗治疗6个月无或低应答的转换组25例。
- 基线及6个月评估SNOT-22、鼻塞评分、鼻阻塞/嗅觉丧失/鼻后滴漏VAS、ACQ-5、AQLQ和鼻息肉总分。
- 采用EUFOREA/EPOS标准评估6个月疾病控制和治疗反应。
主要发现
- 两组所有患者报告结局和鼻息肉总分均显著改善。
- 转换组与初治组在SNOT-22、TNPS、鼻塞评分、嗅觉丧失/鼻阻塞/鼻后滴漏VAS、ACQ-5和AQLQ上疗效相当。
- 6个月良好至优异治疗反应:转换组67%,生物制剂初治组97%。
- 6个月疾病控制:转换组44%,生物制剂初治组67%,嗅觉丧失是未控制主因。
关键数值与推荐
- 治疗反应评估采用EUFOREA/EPOS标准,6个月良好至优异反应转换组67%、初治组97%。
- 疾病控制评估采用EUFOREA/EPOS标准,6个月控制率转换组44%、初治组67%。
临床怎么用
- 对奥马珠单抗或美泊珠单抗应答不佳的CRSwNP患者换用度普利尤单抗仍可获得症状和鼻息肉评分显著改善。
- 转换组达到疾病控制和优异治疗反应的比例低于初治组,尤其需关注嗅觉丧失对疾病控制的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biologicals have revolutionized care for severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). Currently, real-world efficacy (RWE) data of dupilumab in patients who switch to dupilumab after having no or minimal therapeutic response to either omalizumab or mepolizumab are lacking. No comparison has been performed between patients switching from omalizumab or mepolizumab to dupilumab and those receiving dupilumab as their first biological. AIM: 55 CRSwNP patients receiving dupilumab in the RELIBIO trial were divided into those who were biological naive (n = 30) and those who showed no to poor therapeutic response to 6 months therapy with either omalizumab or mepolizumab (n = 25), with evaluation of the following parameters at baseline and 6 months: SNOT-22 scores, nasal congestion scores (NCS), VAS scores for nasal obstruction, smell loss and postnasal drip, ACQ-5, AQLQ and total nasal polyp scores (TNPS). We determined disease control and therapeutic response evaluation (TRE) at 6 months for both groups using the EUFOREA/EPOS criteria. RESULTS: Dupilumab showed significant improvements on all patient-reported outcome measures (PROMs) and TNPS in both groups. When comparing the efficacy between switchers and naive patients, dupilumab showed equal efficacy in both groups on SNOT-22, TNPS, NCS, VAS scores for smell loss, nasal blockage and postnasal drip, ACQ-5 and AQLQ. A good to excellent therapeutic response at 6 months was observed in 67% of switchers compared to 97% of the biological naive patients. Regarding disease control at 6 months, we observed 44% being controlled in the switchers and 67% in the biological naive group, with smell loss being the main reason for not being controlled. CONCLUSIONS: This prospective RWE study shows that dupilumab significantly reduced symptom severity and nasal polyp scores in CRSwNP patients at 6 months of therapy, also in those showing a minimal therapeutic response to mepolizumab or omalizumab. Patients in the biologic naive group showed a higher likelihood of achieving disease control.
引用
- Lammens J, Viskens A, Verstappen G, et al. Real world efficacy of dupilumab in switchers versus biological naive CRSwNP patients. Rhinology. 2026. PMID: 42334397. doi:10.4193/Rhin26.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。